BioPharm International-05-01-2004

BioPharm International

BioPartnering: Global BioPartnering: A Personal Perspective

May 01, 2004

Columns and Departments

17

5

Biotechnology players are emerging in countries that historically have not been substantially active in this industry.

Upgrading a Pharmaceutical Laboratory to Part 11 Compliance

May 01, 2004

Advanced Systems

17

5

FDA's regulation 21 CFR Part 11 on Electronic Records and Electronic Signatures provides industry with the requirements that allow electronic records and signatures in computerized systems in place of paper records and handwritten signatures.1

Regulatory Issues with New and Unlicensed Veterinary Biological Products

May 01, 2004

Veterinary Biologics

17

5

There are six mechanisms for bringing a veterinary biologic into use when circumstances demand a rapid response and full licensure will take too long.

Points to Consider for Human Gene Therapy and Product Quality Control State Food and Drug Administration of China

May 01, 2004

Industry Innovation

17

5

Introduction - Gene therapy is a medical intervention based on the modification of the genetic material of living cells. Currently, gene therapy is restricted in application to somatic cells.

Regulatory Beat: Federal Regulators Weigh New Biotech Controls

May 01, 2004

Columns and Departments

17

5

Government agencies examine the need for more regulation of ?bio-pharming,? biosecurity, and BSE.

The Genesis of Gendicine: The Story Behind the First Gene Therapy

May 01, 2004

Industry Innovation

17

5

In October 2003, Shenzhen SiBiono GeneTech made history by becoming the first company approved to market a gene therapy medication. China's State Food and Drug Administration (SFDA) approved Gendicine for treatment of head and neck squamous cell carcinoma (HNSCC). SiBiono believes that continued clinical trials will prove Gendicine to be effective as a wide-spectrum anticancer agent.

Simulations Improve Production Capacity

May 01, 2004

Advanced Systems

17

5

As biotechnology organizations have successfully launched new products, the challenges of producing adequate quantities have grown. Many companies are now dealing with multiproduct manufacturing facilities and pushing the limits of their capabilities. One result of this complexity is a loss of production capacity due to inefficiencies.

Final Word: BIO: The Olympics of Biotech

May 01, 2004

Columns and Departments

17

5

Plan ahead to make the most of every opportunity at this year?s BIO convention in San Francisco.